1-1, Doshomachi 4-chome
2 articles with Takeda Pharmaceuticals
LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
Takeda gains certain rights to LCB’s antibody-drug conjugate technology, ConjuAll, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.
Fears Nachawati Investigating Possible Uloric Lawsuits After FDA Issues Strongest Warning for Gout Drug
FDA orders boxed warning on packaging after studies confirm death risks